Literature DB >> 34845385

Aumolertinib is effective in NSCLC.

Diana Romero1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34845385     DOI： 10.1038/s41571-021-00586-x

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.

Authors:  Shun Lu; Qiming Wang; Guojun Zhang; Xiaorong Dong; Cheng-Ta Yang; Yong Song; Gee-Chen Chang; You Lu; Hongming Pan; Chao-Hua Chiu; Zhehai Wang; Jifeng Feng; Jianying Zhou; Xingxiang Xu; Renhua Guo; Jianhua Chen; Haihua Yang; Yuan Chen; Zhuang Yu; Her-Shyong Shiah; Chin-Chou Wang; Nong Yang; Jian Fang; Ping Wang; Kai Wang; Yanping Hu; Jianxing He; Ziping Wang; Jianhua Shi; Shaoshui Chen; Qiong Wu; Changan Sun; Chuan Li; Hongying Wei; Ying Cheng; Wu-Chou Su; Te-Chun Hsia; Jiuwei Cui; Yuping Sun; Sai-Hong Ignatius Ou; Viola W Zhu; James Chih-Hsin Yang
Journal:  J Thorac Oncol       Date:  2021-11-19       Impact factor: 15.609
  1 in total
  3 in total

Review 1.  Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors.

Authors:  Shi-Yong Sun
Journal:  Front Med       Date:  2022-09-24       Impact factor: 9.927

2.  Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence.

Authors:  Luyao Ao; Shencun Fang; Kexin Zhang; Yang Gao; Jiawen Cui; Wenjing Jia; Yunlong Shan; Jingwei Zhang; Guangji Wang; Jiali Liu; Fang Zhou
Journal:  J Exp Clin Cancer Res       Date:  2022-05-03

3.  Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series.

Authors:  Shao Feng; Zhang Qiang; Cheng Wanwan; Zeng Zhaozhun; Xie Yuewu; Fang Shencun
Journal:  Front Oncol       Date:  2022-03-29       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.